- Home
- GYRE vs CDTX Comparison
GYRE vs CDTX Comparison
Compare GYRE & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- CDTX
- Stock Information
- Founded
- GYRE 2002
- CDTX 2012
- Country
- GYRE United States
- CDTX United States
- Employees
- GYRE N/A
- CDTX N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GYRE Health Care
- CDTX Health Care
- Exchange
- GYRE Nasdaq
- CDTX Nasdaq
- Market Cap
- GYRE 897.1M
- CDTX 980.1M
- IPO Year
- GYRE N/A
- CDTX 2015
- Fundamental
- Price
- GYRE $7.57
- CDTX $64.85
- Analyst Decision
- GYRE
- CDTX Strong Buy
- Analyst Count
- GYRE 0
- CDTX 11
- Target Price
- GYRE N/A
- CDTX $52.11
- AVG Volume (30 Days)
- GYRE 159.6K
- CDTX 1.1M
- Earning Date
- GYRE 08-12-2025
- CDTX 08-12-2025
- Dividend Yield
- GYRE N/A
- CDTX N/A
- EPS Growth
- GYRE N/A
- CDTX N/A
- EPS
- GYRE 0.02
- CDTX N/A
- Revenue
- GYRE $100,643,000.00
- CDTX $302,000.00
- Revenue This Year
- GYRE $21.04
- CDTX N/A
- Revenue Next Year
- GYRE $89.64
- CDTX N/A
- P/E Ratio
- GYRE $95.15
- CDTX N/A
- Revenue Growth
- GYRE N/A
- CDTX N/A
- 52 Week Low
- GYRE $6.11
- CDTX $10.14
- 52 Week High
- GYRE $19.00
- CDTX $66.20
- Technical
- Relative Strength Index (RSI)
- GYRE 47.42
- CDTX 77.26
- Support Level
- GYRE $7.09
- CDTX $54.91
- Resistance Level
- GYRE $7.63
- CDTX $61.60
- Average True Range (ATR)
- GYRE 0.40
- CDTX 4.62
- MACD
- GYRE 0.03
- CDTX 0.47
- Stochastic Oscillator
- GYRE 42.74
- CDTX 90.19
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.